Omnicell (NASDAQ:OMCL) Upgraded by Wall Street Zen to “Strong-Buy” Rating

Wall Street Zen upgraded shares of Omnicell (NASDAQ:OMCL) from a buy rating to a strong-buy rating in a research note issued to investors on Sunday morning.

A number of other analysts have also recently issued reports on the stock. Weiss Ratings upgraded shares of Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a research note on Thursday. Bank of America raised shares of Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 price target on the stock in a research report on Wednesday, February 4th. KeyCorp lifted their price target on shares of Omnicell from $60.00 to $70.00 and gave the company an “overweight” rating in a research report on Tuesday, April 28th. Piper Sandler reissued an “overweight” rating and issued a $49.00 price target (down from $63.00) on shares of Omnicell in a research report on Friday, February 6th. Finally, Wells Fargo & Company lifted their price target on shares of Omnicell from $52.00 to $55.00 and gave the company an “overweight” rating in a research report on Thursday, April 23rd. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, Omnicell currently has a consensus rating of “Buy” and a consensus target price of $59.86.

Omnicell Price Performance

NASDAQ OMCL opened at $43.82 on Friday. The company has a quick ratio of 1.29, a current ratio of 1.50 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $1.99 billion, a PE ratio of 99.59, a price-to-earnings-growth ratio of 1.10 and a beta of 0.96. The company has a 50 day moving average price of $37.38 and a two-hundred day moving average price of $39.87. Omnicell has a 12-month low of $25.44 and a 12-month high of $55.00.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Tuesday, April 28th. The company reported $0.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.33 by $0.22. The firm had revenue of $309.88 million during the quarter, compared to analysts’ expectations of $304.02 million. Omnicell had a net margin of 1.67% and a return on equity of 4.00%. The company’s revenue was up 14.9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.26 earnings per share. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. As a group, equities analysts predict that Omnicell will post 1.34 earnings per share for the current fiscal year.

Insider Transactions at Omnicell

In related news, EVP Corey J. Manley sold 7,405 shares of the business’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $34.69, for a total transaction of $256,879.45. Following the transaction, the executive vice president owned 96,717 shares of the company’s stock, valued at approximately $3,355,112.73. The trade was a 7.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 2.92% of the company’s stock.

Hedge Funds Weigh In On Omnicell

Institutional investors and hedge funds have recently bought and sold shares of the stock. Raymond James Financial Inc. bought a new stake in Omnicell in the 2nd quarter valued at $26,000. First Horizon Corp bought a new stake in Omnicell in the 3rd quarter valued at $31,000. Farther Finance Advisors LLC increased its holdings in Omnicell by 784.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,168 shares of the company’s stock valued at $36,000 after buying an additional 1,036 shares during the period. Clearstead Advisors LLC increased its holdings in Omnicell by 12,180.0% in the 4th quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock valued at $56,000 after buying an additional 1,218 shares during the period. Finally, Kemnay Advisory Services Inc. bought a new stake in Omnicell in the 4th quarter valued at $58,000. Institutional investors own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.